Liver kidney microsomal type 1 antibody

Liver Kidney Microsomal Type 1 Antibody (LKM1) is a type of autoantibody that targets specific proteins found in the liver and kidney. These antibodies are often associated with certain types of autoimmune diseases, including Autoimmune Hepatitis (AIH) and Type 1 Diabetes.

Overview[edit | edit source]

The LKM1 antibody is one of the three types of antibodies that are typically present in individuals with autoimmune hepatitis. The other two types are Smooth Muscle Antibody (SMA) and Antinuclear Antibody (ANA). LKM1 antibodies are particularly associated with Type 2 AIH, a less common form of the disease that primarily affects children and young adults.

Clinical Significance[edit | edit source]

The presence of LKM1 antibodies in the blood is a significant marker for Type 2 AIH. These antibodies are found in approximately 80-95% of patients with this form of the disease. In addition, LKM1 antibodies can also be found in some patients with Hepatitis C and in a small percentage of patients with Type 1 Diabetes.

Detection[edit | edit source]

The detection of LKM1 antibodies is typically done through a blood test. The test involves the use of Indirect Immunofluorescence (IIF), which allows for the visualization of these antibodies under a microscope. A positive result indicates the presence of the antibodies, but further testing is usually required to confirm the diagnosis of Type 2 AIH.

Treatment[edit | edit source]

The treatment for conditions associated with LKM1 antibodies typically involves the use of medications to suppress the immune system and reduce inflammation in the liver. This may include Corticosteroids and other Immunosuppressive drugs. In severe cases, a Liver Transplant may be necessary.